The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...

Positive clinical trial results for Merck & Co's experimental antiviral COVID-19 pill reverberated through the healthcare sector on Friday, sending the drugmaker's stock price soaring while ...

BioNTech will make $800mn in upfront payments to Biotheus, a drugmaker based in Guangdong province, with milestone payments of up to $150mn. Uğur Şahin, chief executive of BioNTech, said the company ...

While Merck's oral drug Molnupiravir has already been cleared by the United Kingdom to treat COVID-19, a Paraguayan laboratory has filed for its emergency registration in the South American ...

Merck KGaA is a healthcare/pharma company that I have been covering and investing in for about 2 years at this point. Q2 2024 ...

Overall, the attraction of Pfizer as an investment is its level of diversification with several different growing drug ...

WASHINGTON--Drugmaker Merck asked U.S. regulators Monday to authorize its pill for treating COVID-19 in what would add an entirely new and easy-to-use weapon to the world's arsenal against the ...

We recently made a list of UBS’ Best Stocks In The AI, Growth & Low Rates Era: Top 29 US Stocks. In this piece, we will take ...

The information, however, is not in the label because the drug — originally manufactured by Merck — was never fully tested in this population. And the company has refused to update the language.

Belen Garijo took charge of German drug-to-semiconductor group Merck KGaA with the tailwind of the Covid pandemic, propelling the stock to an all-time high in 2021. Since then, the shares have ...

Merck & Co. Inc.’s stock rose 1.4% premarket Thursday, after the drug company beat profit and sales estimates for the third quarter, offsetting lowered guidance due to deals with partners Curon ...

(Nasdaq: GILD) announced today its third quarter 2024 results of operations. "Gilead’s third quarter results are the strongest of the year to date, with 7% year-over-year revenue growth, including 13% ...